Steroids are the first line treatment in warm<unk> ; with oral prednisone achieving an 80% initial response rate, with a 30-40% sustained remission rate at 1 year. Steroids may be decreased at 3 weeks and tapered at 3-6 months depending on the response. Rituximab may be added to initial management to increase the response rate, or it may be used in cases of severe disease such as IgA mediated warm<unk> , mixed<unk> , Evans syndrome or in cases of high hemolysis levels). If a response cannot be achieved with steroids or rituximab, splenectomy can be done. Other third line options, that are less studied, include azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil and bortezomib. The treatments for secondary warm<unk>  are generally the same as primary warm<unk> , but with the addition of treating the underlying disease if possible. Steroids are not indicated in the treatment of cold agglutinin disease due to low response rates. Cases of cold agglutinin disease with mild anemia with limited and compensated hemolysis can be monitored with adjunct supportive care (such as avoidance of cold exposure or thermal protection to prevent against hemolysis). Rituximab is used to treat pathogenic B-cell clones in cold agglutinin disease with response rates of 45-60%. Relapses are common upon discontinuation of rituximab, but the medication can be restarted to achieve subsequent remission. Rituximab can be combined with bendamustine to achieve a 71% overall and 40% complete response rate with an increased response seen with prolonged therapy (with a time to best response at a median of 30 months) due to the drugs' effect on long lived plasma cells. Splenectomy is less efficacious in cold agglutinin disease. Special considerations are required when treating people with<unk>  using blood transfusion. In cold agglutinin disease; the patient and the extremity should be kept warm during transfusion to prevent agglutination and hemolysis of the donor and patient red blood cells. In warm<unk> ; cross-matching of blood will show incompatibility so it is recommended to perform a bedside in vivo compatibility test prior to infusion. Erythropoietin (EPO) has been shown to increase hemoglobin levels in cold and warm<unk> .
Autoimmune hemolytic anemia
Mixed autoimmune hemolytic anemia
Cold autoimmune hemolytic anemia
Acquired hemolytic anemia
Microangiopathic hemolytic anemia
Mechanical hemolytic anemia
Drug-induced nonautoimmune hemolytic anemia
Cryoglobulinemia